Full history for every metric is available with a Kvantra account
Taro Pharmaceutical Industries Ltd. (TARO)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 670 | 645 | 549 | 561 | 573 | 629 | 629 |
| Operating profit | $m | 22 | 21 | |||||
| Net profit | $m | 282 | 244 | -401 | 58 | 25 | 54 | 54 |
| EPS reported | $ | 1.43 | 1.44 | |||||
| Operating cashflow per share | $ | 3.52 | 3.52 | |||||
| Capex per share | $ | 1.44 | 1.44 | |||||
| FCF per share | $ | 2.08 | 2.08 | |||||
| Free cash flow | $m | 78 | 74 | |||||
| Net debt | $m | -879 | -879 | |||||
| Book value equity | $m | 1,793 | 1,793 | |||||
| Book value per share | $ | 47.71 | 47.71 | |||||
| Number of shares | m | 37.58 | 37.58 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 29.61 | - | |||||
| P/B LTM | x | 0.89 | 0.90 | |||||
| P/S LTM | x | 2.52 | 2.57 | |||||
| P/FCF LTM | x | 20.30 | 21.77 | |||||
| EV/EBITDA LTM | x | 31.88 | 12.00 | |||||
| EV/Sales LTM | x | 1.95 | 1.17 | |||||
| Earnings Yield LTM | % | 3.38% | 3.33% | |||||
| FCF Yield | % | 4.92% | 4.59% | |||||
| Quality | ||||||||
| ROE | % | 3.00% | 3.06% | |||||
| ROIC | % | 0.78% | 0.78% | |||||
| Operating margin | % | 3.42% | 3.42% | |||||
| Gross margin | % | 48.47% | 48.47% | |||||
| FCF/Sales | % | 12.42% | 12.42% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | +110.29% | +110.29% | |||||
| Sales Growth YoY | % | +9.81% | +9.81% | |||||
| Net Income Growth YoY | % | +111.70% | +111.70% | |||||
| FCF Growth | % | +462.25% | +462.25% | |||||
| Operating Profit Growth | % | +21.42% | +21.42% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | -9.45 | -9.45 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -55.40% | -54.44% | |||||
| Net debt/Equity | x | -0.49 | -0.49 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Taro Pharmaceutical Industries Ltd. operates as a scientifically-driven pharmaceutical enterprise, specializing in the development, manufacturing, and commercialization of both prescription and over-the-counter medications. Its market reach spans the United States, Canada, Israel, and various other international territories. The company also produces active pharmaceutical ingredients (APIs), primarily for integration into its own finished dosage form products. Its extensive product catalog addresses a broad spectrum of medical conditions and therapeutic areas, encompassing treatments for allergies, pain (analgesic), bacterial and fungal infections (antibacterial, antibiotic, antifungal), seizures (anticonvulsant), nausea (antiemetic), inflammation (anti-inflammatory), cancer (anti-cancer, topical anti-neoplastic), blood clot prevention (antiplatelet agent), fever reduction (antipyretic), cardiovascular issues, central nervous system disorders, hormonal regulation (corticosteroid, endocrine), cosmetic applications, coughs and colds, dermatological complaints, fluid management (diuretic), gastrointestinal problems, constipation (laxative), severe pain (narcotics), neuropathic pain, neuropsychiatric conditions, and sleep/anxiety management (sedative/hypnotic). These pharmaceutical goods are available in numerous formats, including capsules, creams, drops, emulsions, gels (and gel kits), granules, injectables, lotions, oils, ointments, pastes, powders (and powders for solution), rectal suppositories, shampoos, solutions (and solutions for infusion), sprays, suspensions, syrups, tablets, toothpastes and mouthwashes, topical foams, and topical solutions. Taro distributes and sells its products directly to a wide array of clients, such as pharmaceutical wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, other direct purchasers, and various healthcare institutions and private pharmacies. The company was established in 1950, with its main offices situated in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a wholly-owned subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Taro Pharmaceutical Industries Ltd. (TARO)
Taro Pharmaceutical Industries Ltd. operates as a scientifically-driven pharmaceutical enterprise, specializing in the development, manufacturing, and commercialization of both prescription and over-the-counter medications. Its market reach spans the United States, Canada, Israel, and various other international territories. The company also produces active pharmaceutical ingredients (APIs), primarily for integration into its own finished dosage form products. Its extensive product catalog addresses a broad spectrum of medical conditions and therapeutic areas, encompassing treatments for allergies, pain (analgesic), bacterial and fungal infections (antibacterial, antibiotic, antifungal), seizures (anticonvulsant), nausea (antiemetic), inflammation (anti-inflammatory), cancer (anti-cancer, topical anti-neoplastic), blood clot prevention (antiplatelet agent), fever reduction (antipyretic), cardiovascular issues, central nervous system disorders, hormonal regulation (corticosteroid, endocrine), cosmetic applications, coughs and colds, dermatological complaints, fluid management (diuretic), gastrointestinal problems, constipation (laxative), severe pain (narcotics), neuropathic pain, neuropsychiatric conditions, and sleep/anxiety management (sedative/hypnotic). These pharmaceutical goods are available in numerous formats, including capsules, creams, drops, emulsions, gels (and gel kits), granules, injectables, lotions, oils, ointments, pastes, powders (and powders for solution), rectal suppositories, shampoos, solutions (and solutions for infusion), sprays, suspensions, syrups, tablets, toothpastes and mouthwashes, topical foams, and topical solutions. Taro distributes and sells its products directly to a wide array of clients, such as pharmaceutical wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, other direct purchasers, and various healthcare institutions and private pharmacies. The company was established in 1950, with its main offices situated in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a wholly-owned subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free